In recent studies, anti-angiogenic compounds have proved to be effective in IBD models.(68) TSP1 in combination with irinotecan inhibited tumor growth in a model of colon cancer xenograft.(69) ABT-510, a peptide derived from TSP1 has been studied in clinical studies (phase I and II for lymphoma and osteosarcoma). Here, THBS1 is linked to neoplasm.